Updates in Pediatric CNS Malignancies: Ependymoma, Germ Cell Tumors and Medulloblastoma - 2020 Annual Meeting
Over the last three years, results have been reported on large and/or national/international clinical trials in pediatric CNS tumors and radiotherapy. This course will update the learner on the important key points to note in how to treat ependymoma, germ cell tumors and medulloblasotma in the 21st century. Target definition, molecular classification and the use of systemic therapy will be addressed.
This activity is available from February 15, 2021, through 11:59 p.m. Eastern time on February 14, 2024.
This activity was originally recorded at ASTRO’s virtual 2020 Annual Meeting, October 23-28th.
The activity is designed to meet the interests of radiation oncologists, radiation dosimetrists, and radiation oncology residents.
Upon completion of this activity, learners should be able to:
- Discuss the management of ependymoma.
- Explain the role of radiotherapy in treatment of CNS germ cell tumors.
- Determine the treatment course for medulloblastoma.
- Nicole A. Larrier, MD, MS is employed at Duke University Medical Center and has no financial relationships with a commercial interest.
- Thomas E. Merchant, DO, PhD is employed at St. Jude Children's Research Hospital and has investment interest from Philips Healthcare.
- Erin S. Murphy, MD is employed at Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic and has no financial relationships with a commercial interest.
- Tamara Z. Vern-Gross, DO, FAAP is employed at Department of Radiation Oncology, Mayo Clinic and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.